ArticleMolecular diversity2026
Hybrid APSO-Bayesian optimized triple-kernel SVR models for QSAR and rational design of 1H-pyrrolo[2,3-c]pyridine-based LSD1 Inhibitors.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysine-specific demethylase 1 (LSD1) is a critical therapeutic target for acute myeloid leukemia. This study developed quantitative structure-activity relationship models to predict the inhibitory activity of 1H-pyrrolo[2,3-c]pyridine-based compounds. Five models were established using heuristic method, XGBoost, and support vector regression (SVR). A triple-kernel SVR model, integrating Radial Basis Function, Polynomial, and Linear kernels, was constructed to capture linear and non-linear patterns, optimized via a hybrid Adaptive Particle Swarm Optimization and Bayesian strategy. Rigorous validation metrics demonstrated that this model achieved highly competitive generalization ([Formula: see text], [Formula: see text]). Interpretation of descriptors highlighted that the electronegativity of the nitrogen atom and hydrogen bond accepting capabilities are critical determinants for LSD1 inhibitory activity. Insights from this model guided the rational design of novel derivatives, whose favorable binding interactions were corroborated by molecular docking. To further explore these findings, 100 ns molecular dynamics simulations were performed on the lead candidate, Compound 46c. The complex exhibited high structural stability. MM/PBSA calculations revealed robust spontaneous binding affinity ([Formula: see text] kcal/mol), primarily driven by van der Waals interactions. Notably, trajectory analysis identified a persistent hydrogen bond with residue LEU183 as a critical stabilizer. Future work will focus on the synthesis and in vitro anticancer evaluation of the designed candidates, particularly Compound 46c, to evaluate their therapeutic potential.
Indexed as
Identifiers
42133162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.